Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 9th Preview)
-
Novartis clinical setbacks in cardiology and neuromuscular disease
Novartis reported two major late-stage setbacks in rapid succession, including the Phase III failure of delpacibart etedesiran (del-desiran) in myotonic dystrophy type 1 and the Phase III failure of pelacarsen in lipoprotein(a) cardiology outcomes. In DM1, the HARBOR trial missed its primary endpoint of statistically significant improvement versus placebo in video Hand Opening Time through week 54. Novartis said it is evaluating the full dataset and will engage with authorities on the program’s development path, with Shreeram Aradhye, president of development and CMO, noting that setbacks are part of scientific progress. For pelacarsen, Novartis and Ionis acknowledged that the Phase III Lp(a)HORIZON trial failed to reduce the risk of cardiovascular events compared with placebo. The outcome adds to pressure on Lp(a)-lowering strategies after other cardiovascular outcomes failures, sharpening scrutiny on whether biomarker reductions can reliably translate into clinical benefit. Together, the two Phase III misses mark a heavy hit to Novartis’ late-stage risk profile and increase uncertainty around both antisense-led and antibody–oligonucleotide conjugate approaches in complex disease areas.
-
FDA approval for AstraZeneca oral SERD in ESR1-mutant advanced breast cancer
The FDA granted accelerated approval to AstraZeneca’s camizestrant (Etcamah) for certain patients with HR+/HER2– advanced breast cancer with ESR1 mutations after the company’s April advisory committee vote went against the drug. The approval is based on the Serena-6 Phase III program, which met progression-free survival, alongside Guardant Health’s Guardant360 companion diagnostic to identify ESR1 mutations. The FDA’s decision contrasts with the panel’s concerns that the randomized treatment switch was supported only by ESR1 detection at an earlier disease point. Analysts said the decision creates a defined, though not unlimited, opportunity for the SERD, while AstraZeneca gets a new line of clinical differentiation versus existing endocrine therapy strategies. For developers of targeted endocrine therapies, the approval reinforces how diagnostic-linked trial designs and endpoint tradeoffs continue to shape regulatory outcomes.
-
Roivant advances pulmonary hypertension program after Phase 2 win
Roivant reported a Phase 2 success for mosliciguat in interstitial lung disease, with the inhaled therapy meeting key endpoints that could open a path into broader lung-disease programs. In a 16-week study, Roivant said mosliciguat achieved a statistically significant 56% reduction versus placebo in pulmonary vascular resistance, alongside improvements on six-minute walk distance and NT-proBNP. The company positioned the results as surpassing Wall Street’s benchmarks for success. The announcement follows Roivant’s history of licensing and repurposing late-stage assets across respiratory indications, and it adds momentum for investors seeking clinical validation for a non-invasive option targeting pulmonary vascular physiology. For the lung landscape, the readout strengthens the case that targeted inhaled vasomodulation may translate into measurable functional and biomarker changes in patients.
-
GSK expands antibody conjugate portfolio through Hutchmed KRAS/EGFR asset deal
GSK took ex-China rights to Hutchmed’s HMPL-A830 in a deal worth up to $1.295 billion, plus royalties, as the UK pharma deepens its push into antibody–drug conjugate (ADC) and related conjugate platforms. GSK will pay $110 million upfront for the preclinical dual-mode-of-action asset, which links an anti-EGFR antibody to a small-molecule KRAS inhibitor payload. The construct is designed to deliver the inhibitor to EGFR-expressing tumors while blocking both EGFR and KRAS signaling pathways. The agreement reflects continued partner interest in precision oncology payload delivery systems and the ongoing effort by large pharma to build scalable programs around both targets and delivery mechanisms. For Hutchmed, it validates the strategic value of its antibody conjugate pipeline outside home-market rights, while for GSK it diversifies a development portfolio around next-generation targeted therapies.
-
Fortrea acquires Worldwide Clinical Trials’ early phase unit for $45M
Fortrea agreed to buy Worldwide Clinical Trials’ early phase services business in a $45 million transaction, aiming to add early clinical pharmacology and bioanalytical capacity to support sponsor demand. The acquisition adds three Texas facilities, including a 200-bed clinical pharmacology unit in San Antonio, a bioanalytical lab in Austin, and a biospecimen storage site in Pflugerville. Fortrea said the move is intended to create a more cohesive early development experience for large- and small-molecule programs. Worldwide indicated the sale will help accelerate investment in late-stage services and technology while expanding geographic coverage. For the CRO market, the deal is another consolidation step targeting end-to-end capability in early development, a segment sponsors increasingly evaluate as timelines and operational flexibility become differentiators.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.